Liontrust GF SF Pan-European Growth Fund

The Fund returned -13.8% over the quarter in euro terms, underperforming the MSCI Europe Index’s -5.3% (which is the comparator benchmark)*^†.

We have written at length about the current headwinds for our quality growth investment style, with longer-duration companies hit harder by fears of inflation and interest rate hikes intended to control it. Equities, broadly speaking, had a stronger March but we reiterate those comments, especially if this year remains volatile. In short, over the 21 years we have managed the Sustainable Future funds, we have seen many periods of inflation and interest rate shifts. During these, we have remained resolutely focused on the long-term prospects of our high-quality companies that can grow profitably year after year by making the world a better place. Our experience is that the long-term success of our investments will be determined by the compounding of growth, not the discount rate shifting up a few per cent.

Of course, this situation has been exacerbated by the conflict in Ukraine but while we are following events closely, we do not attempt to forecast macroeconomic or geopolitical factors. We continue to focus on our core competence: identifying businesses exposed to strong sustainability trends that will endure and grow their value per share regardless of economic backdrop. At times of indiscriminate sell-offs, the market presents us with opportunities to add to our highest-conviction companies at more attractive valuations, as well as starting positions in names we have long admired but, prior to now, were fairly valued by the market, and we introduced two new investments over the quarter.

Our first addition was Oxford BioMedica, a long-term holding in our UK portfolios, under the Enabling innovation in healthcare theme. Shares have been falling since November, which we find hard to understand as, operationally, the business has never looked stronger. It may see less demand for AstraZeneca vaccine manufacturing as the pandemic appears to be receding but this is being replaced by higher value contracts with partners developing ground-breaking gene therapies.

Oxford BioMedica is a leader in lentiviral vector innovation and manufacture, one of the core delivery mechanisms within gene and cell therapies. We believe such treatments are set to revolutionise the healthcare landscape, as they have the potential to provide a one-off cure to underlying diseases versus the current chronic therapy paradigm, where patients are expected to take medication or treatment for the rest of their lives. As with many healthcare companies, there is a risk some pipeline therapies are unsuccessful but one of the core reasons we like Oxford BioMedica is that it has broad exposure to innovation as a whole and to other organisations working in gene and cell therapy.

Netcompany was a second purchase over the quarter, an IT services company with a consulting business model, held under our Improving the resource efficiency of industrial and agricultural processes theme. The company’s thousands of IT engineers help businesses across sectors to modernise and digitise their operations, improving efficiency, customer experience, resilience and digital security. Netcompany works on a fixed cost basis and this is key to winning projects (particularly in the public sector), assuring clients it will deliver the project both on time and on budget.

We see a major trend towards digitalisation in Europe, with the EU launching a huge stimulus package called The Recovery and Resilience Facility in response to Covid. The fund amounts to over €800 billion to be spent over the next five years, with the goal to stimulate and modernise the European economy, increase growth and transition to a lower-carbon digital future.

We like the culture of the business in that it remains IT people leading IT people, with the founders engineers by training and looking to keep the same technical leadership. The company recently made a large acquisition in the shape of Intrasoft and is taking a slow and steady approach to integration, keeping this as a separate entity and shifting it to the Netcompany model. Finally, the current 25x PE valuation is close to cashflows given the capital-light nature and for the returns and growth profile, we believe this is an undemanding multiple.

In terms of other trades over the quarter, we sold IP Group under the Enabling innovation in healthcare theme on risk management and liquidity grounds, having added Oxford Nanopore – IP’s largest investment, which listed with an IPO in September – in Q4.

Over a volatile period marked by indiscriminate selling, our positive names were either financials amid the value rotation, including DNB Bank and Axa, or benefited from strong results such as French payment company Edenred. The latter is a good fit for our Improving the resource efficiency of industrial and agricultural processes theme, with its payment solutions bringing efficiency and value for money for customers. Edenred announced record earnings and growth for 2021 over the quarter, with this cash generation allowing the business to strengthen its financial profile and propose a higher dividend than before the pandemic, while also maintaining an ambitious M&A strategy.

Global catering business Compass Group, held under our Leading ESG management theme, also had a solid Q1, with the company reporting a solid first quarter of its financial year (to end December), during which it spent a further £87 million on bolt-on acquisitions in the US. Despite some concerns about impact from the Omicron variant in Q2, its guidance for FY22 remains unchanged.

Befesa reported record earnings levels for both Q4 and FY 2021 in March, delivering strong double-digit growth year-on-year and results well above pre-pandemic levels. Held under our Delivering a circular materials economy theme, these positive earnings developments were primarily driven by strong base metal prices and good volume performance, including the acquisition of US firm AZR in the middle of August.

Meanwhile, London Stock Exchange shares rallied as the group announced plans to sell a group of assets known as BETA+ for US$1.1 billion to private equity firm Motive Partners and investment firm Clearlake Capital Group. The BETA+ platforms deal with securities processing, custody, clearing, and asset servicing, as well as cost and tax basis reporting software and front-end client solutions. LSEG said its data and analytics business will target mid-single digit annual revenue growth in the medium term following the divestment of BETA+.

Among weaker performers are generally our fastest-growing companies that are not yet profitable from a P&L perspective. These continue to reinvest and grow in their nascent markets, developing their products and services, growing their headcount and building strong competitive advantages.

Trustpilot, for example, is becoming the world’s leading review platform, allowing an independent and objective space for customers and merchants to interact online. As the economy continues to digitise, we believe Trustpilot’s dominant position in this fast-growing market will result in strong cashflow generation over the long term with millions of reviewers and merchants on this two-sided platform. The shares have dropped precipitously since IPO in March 2021, yet the results continue to positively surprise us. We have added to the position on weakness and remain confident in our thesis.

Elsewhere, Zur Rose is another strong example of a company driving digitisation. Operating under the Doc Morris brand, it is Europe’s leading digital pharmacy, providing over-the-counter products to over 12 million users. The German market presents a huge opportunity, valued at over €60 billion per annum, and is poised for disruption, with a recent change in legislation mandating the use of digital prescriptions. This shift has been delayed due to the recent Omicron variants hampering the technology roll-out, however, sending Zur Rose’s share price down over 50%. After review, we do not believe this delay will change the long-term direction of this market and added to this position on weakness.

Spotify’s shares have also been weak following its 2021 fourth-quarter results released at the start of February. The results for the quarter itself were solid and generally in line with analyst expectations but the company’s guidance on Q1 2022 was slightly below what the market had been expecting in terms of new monthly subscribers, which Spotify put down to an increasingly seasonal approach to marketing and acquiring new customers. The company also announced it would be no longer providing annual guidance, just focusing on the next quarter. Any company that gives less information to the market is generally looked on with great suspicion. Spotify, however, is led by the founder Daniel Ek, who comes across as extremely thoughtful and very focused on the long term and, as such, this is not something that concerns us.

Finally, despite generating positive cash flows, Spotify posted another year of accounting losses and in this market, companies not seen as generating profits today seem to be punished more than most. Although predicting the future margin profile of this business is difficult, we believe expansion is likely to follow as it continues to grow in scale, as well as grow high-margin lines such as podcasts or the marketplace business. Spotify shares are now trading at 1.7x 2022 sales – this is the lowest multiple on which the business has traded since listing in 2018 and 25% below the 2.2x it fell to during Covid. As such, we believe our internal rate of return is likely to be driven by revenue growth from here, with potential for re-rating if sentiment in the market turns.

Meanwhile, Avanza Bank, the largest savings and investment platform in Sweden, has seen its price fall over 40% from the peak seen in November 2021. Avanza’s earnings are correlated to several factors, all of which are impossible to predict, including broader market levels, interest rates, and volatility of markets. 2021 was a fantastic year for the business, where earnings reached all-time highs because of a larger-than-ever customer base, high levels of trading activity, and high absolute market levels. It is therefore likely Avanza will earn less in 2022 than in 2021, while the company continues to reinvest in people and products to maintain its competitive advantage – it is around four times larger than the nearest competitor in Sweden.

As long-term investors, however, we care about what the company is likely to earn five years from now, and its relentless focus on customer satisfaction, alongside an efficient platform, means we are confident the earnings power of the business will be significantly larger in the future. After weakness in the shares, the company trades on around 20x next year’s earnings – a similar multiple to the trough reached during the Covid selloff in 2020.

Finally, Hargreaves Lansdown’s shares fell on the back of interim results and its Capital Markets Day in February. Net new business and earnings per share were weaker than consensus expectations and the company also announced a suspension of special dividends and a higher cost trajectory for the next couple of years as it plans to reinvest in the business. We think these investments are the right thing to do for the long term, helping HL maintain its market-leading position, but they have taken too long to make and are not without execution risk.

We continue to believe this is one of the better businesses in the UK but have concerns over management quality. Due to the de-rating of the shares and the exposure to our Saving for the future theme, we maintain a position but prefer other names in this space such as St James’s Place.

Key Features of the Liontrust GF SF Pan-European Growth Fund

Notes: ¹As specified in the KIID of the fund; ²SRRI = Synthetic Risk and Reward Indicator. Please refer to the KIID for further detail on how this is calculated.

Discrete years' performance*, to previous quarter-end:
Past performance does not predict future returns.

*Source: FE Analytics, as at 31.03.22, primary share class, in euro terms, total return, net of fees and income reinvested.

KEY RISKS

Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested.

The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.

Some of the Funds managed by the Sustainable Future team involve foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. Investment in Funds managed by the Sustainable Future team involves foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. The value of fixed income securities will fall if the issuer is unable to repay its debt or has its credit rating reduced. Generally, the higher the perceived credit risk of the issuer, the higher the rate of interest. Some Funds may invest in derivatives. The use of derivatives may create leverage or gearing. A relatively small movement in the value of a derivative's underlying investment may have a larger impact, positive or negative, on the value of a fund than if the underlying investment was held instead.

DISCLAIMER

This is a marketing communication. Before making an investment, you should read the relevant Prospectus and the Key Investor Information Document (KIID), which provide full product details including investment charges and risks. These documents can be obtained, free of charge, from www.liontrust.co.uk or direct from Liontrust. Always research your own investments. If you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.

This should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets. It contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, forwarded, reproduced, divulged or otherwise distributed in any form whether by way of fax, email, oral or otherwise, in whole or in part without the express and prior written consent of Liontrust. Always research your own investments and if you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.